---
title: "Lysergide (DT120) in Generalized anxiety disorder: Definition and etiology"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Definition and etiology. Topics: Definition: persistent, excessive, and difficult-to-control worry about everyday concerns; Definition: core features of generalized anxiety disorder under DSM-5 and ICD-11; Classification: one of the anxiety disorders, occurring in childhood and adulthood; Diagnostic history: from DSM-III to the 6-month duration criterion; 9 further topics. 13 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/definition-and-etiology"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Definition and etiology

<a id="heading-2.2.1.1"></a>

## 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

### Definition: persistent, excessive, and difficult-to-control worry about everyday concerns

> “The disorder is characterized by persistent, excessive, and unrealistic worry about everyday concerns. Worry may involve multiple areas, including finances, family, health, and the future. Excessive worry is difficult to control and is often accompanied by nonspecific psychological and physical symptoms. Excessive worry is the central feature of generalized anxiety disorder.”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

> “Generalized anxiety disorder is characterized by excessive anxiety and worry about a variety of events or activities (e.g., work or school performance) that occurs more days than not, for at least 6 months. People with generalized anxiety disorder find it difficult to control their worry, which may cause impairment in social, occupational, or other areas of functioning.”

Source: [National Institute of Mental Health generalized anxiety disorder statistics](https://www.nimh.nih.gov/health/statistics/generalized-anxiety-disorder)

<a id="topic-2.2.1.1-2"></a>

### Definition: core features of generalized anxiety disorder under DSM-5 and ICD-11

| Feature | Generalised anxiety disorder |
| --- | --- |
| Core emotions or cognitions | “Marked, uncontrollable, and anxious worry and fears about everyday events and problems” |
| Physical symptoms | “Restlessness, fatigue, irritability, difficulty concentrating, muscle tension, sleep disturbance, or autonomic arousal” |
| Behaviour | “Disturbance impairs social, school, work, or other functioning” |
| Median age of onset | “Adulthood (around 30 years)” |

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

<a id="topic-2.2.1.1-3"></a>

### Classification: one of the anxiety disorders, occurring in childhood and adulthood

> “Anxiety disorders comprise separation anxiety and selective mutism (occurring primarily in childhood; between the ages of 4 years and 18 years), specific phobias, social anxiety disorder, and generalised anxiety disorder (occurring in childhood as well as in adulthood), as well as panic disorder and agoraphobia (occurring primarily in adulthood; from the age of 18 years and older).”
> “Fear is a conscious feeling evoked by threat or impending danger, whereas anxiety involves anticipation of real or imagined future threat or danger.”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

<a id="topic-2.2.1.1-4"></a>

### Diagnostic history: from DSM-III to the 6-month duration criterion

> “The American Psychiatric Association first introduced the diagnosis of generalized anxiety disorder in the DSM-III.”
> “Based on these findings, the DSM-III-R committee on generalized anxiety disorder recommended increasing the required duration to 6 months. The final version of the DSM-III-R incorporated this change. The DSM-IV subsequently revised the definition of excessive worry and the required number of associated psychophysiological symptoms.”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

<a id="topic-2.2.1.1-5"></a>

### Etiology: contributing factors

> “The etiology of generalized anxiety disorder may include:”
> “Medical conditions, such as diabetes”
> “Comorbid mental health conditions, such as depression”
> “Genetic factors, with generalized anxiety disorder occurring in approximately 25% of first-degree relatives of affected patients”
> “Environmental factors, such as childhood abuse”
> “Substance use disorder”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

<a id="topic-2.2.1.1-6"></a>

### Heritability: family and twin studies

> “The calculated summary odds ratios ranged from 4 to 6, depending on the disorder. Only for panic disorder and generalized anxiety disorder could the authors identify more than one large-scale twin study for meta-analysis. These yielded heritabilities of 0.43 for panic disorder and 0.32 for generalized anxiety disorder. For panic disorder, the remaining variance in liability could be attributed primarily to nonshared environment. For generalized anxiety disorder, this was true for men, but for women, a potentially significant role for common familial environment was also seen.”

Source: [Hettema et al. (2001)](https://pubmed.ncbi.nlm.nih.gov/11578982/)

> “Heritability of anxiety disorders can vary, but heritability estimates converge to rates of between around 35% for generalised anxiety disorder and around 50% for social anxiety disorder, panic disorder, and agoraphobia.”
> “The mode of inheritance is complex, with many genetic variants of small effect interacting with, or adding to, other (presumably non-shared environmental) risk factors.”
> “However, genome-wide association studies showed a high genetic correlation (rG>0·6) among people with anxiety, depression, and neuroticism,”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

> “It is estimated that genes contribute 30% to 50%”
> “to the development of an anxiety disorder. Conversely, development of an anxiety disorder due to non-genetic factors is approximately 50% to 70%.”

Source: [Patriquin and Mathew (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5832062/)

<a id="topic-2.2.1.1-7"></a>

### Common genetic variants: genome-wide association meta-analysis of 122,341 cases of major anxiety disorders

> “The major anxiety disorders (ANX; including generalized anxiety disorder, panic disorder and phobias) are highly prevalent, often onset early and cause substantial global disability.”
> “Here, we present a genome-wide association meta-analysis comprising 122,341 European ancestry ANX cases and 729,881 controls. We identified 58 independent genome-wide significant risk variants and 66 genes with robust biological support.”
> “As predicted by twin studies, we found substantial genetic correlation between ANX and depression, neuroticism and other internalizing phenotypes.”
> “The SNP-based heritability estimated at 10.1% captures approximately one-quarter of the broad-sense heritability from twin studies of adult ANX”

Source: [Strom et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12900644/)

<a id="topic-2.2.1.1-8"></a>

### Common genetic variants: UK Biobank genome-wide association study of lifetime anxiety disorder

> “Anxiety disorders are common, complex psychiatric disorders with twin heritabilities of 30–60%.”
> “The liability scale common variant heritability estimate for Lifetime Anxiety Disorder was 26%, and for Current Anxiety Symptoms was 31%.”
> “Anxiety showed significant positive genetic correlations with depression and insomnia as well as coronary artery disease, mirroring findings from epidemiological studies.”

Source: [Purves et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7237282/)

<a id="topic-2.2.1.1-9"></a>

### Common genetic variants: Million Veteran Program genome-wide association study of GAD-2 score

> “The authors identified five genome-wide significant signals for European Americans and one for African Americans on GAD-2 score.”

Source: [Levey et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7869502/)

<a id="topic-2.2.1.1-10"></a>

### Environmental risk factors: adverse life events and parenting

> “The development of GAD is associated with unexpected negative life events (Nordahl et al. 2010), maltreatment (Moffitt et al. 2007), and loss (Kendler et al. 2003).”
> “In addition to one-time events, as outlined below, those with GAD have increased likelihood of negative experiences that are more chronic in nature, including ongoing abuse, parental rejection, inconsistent parenting, and parental invalidation (Cougle et al. 2010, Moffitt et al. 2007).”
> “GAD symptoms in children and adolescents have also been associated with harsh parental discipline and parenting characterized by strict rules and high expectations (Shanahan et al. 2008) as well as parental overprotection (Beesdo et al. 2010, Nordahl et al. 2010).”

Source: [Newman et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4964851/)

> “Environmental factors that influence the risk for anxiety disorders at multiple timepoints include various stressful life experiences and parenting practices, including childhood trauma, separation from attachment figures, and forms of overprotective parenting that limit children’s opportunities to encounter frightening circumstances in ways that facilitate mastery.”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

<a id="topic-2.2.1.1-11"></a>

### Temperament: behavioral inhibition

> “Strong findings exist for the temperament of behavioural inhibition, expressed as reduced movement and vocalisation in the presence of novelty.”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

<a id="topic-2.2.1.1-12"></a>

### Sociodemographic correlates: NESARC, United States adults

> “Data are taken from a large (n=43093) representative sample of the adult USA population.”
> “Being female, middle-aged, widowed/separated/divorced, and low income increased risk, while being Asian, Hispanic, or Black decreased risk.”

Source: [Grant et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16202187/)

<a id="topic-2.2.1.1-13"></a>

### Sponsor statement on causes of generalized anxiety disorder

> “GAD may run in families, but the exact cause of the disorder is unknown. Research suggests that GAD results from a mix of genetics, brain chemistry, biology, and environment. Researchers have found that external causes, such as experiencing a traumatic event or being in a stressful environment, may put a person at higher risk for developing GAD.”

Source: [Definium Therapeutics GAD fact sheet (2026)](https://definiumtx.com/wp-content/uploads/2026/07/DFTX-FactSheet-GAD-072326.pdf)

Additional sources: [Stein and Sareen (2015)](https://pubmed.ncbi.nlm.nih.gov/26580998/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
